Rediscovery of antimicrobial peptides as therapeutic agents

In recent years, the occurrence of antibiotic-resistant pathogens is increasing rapidly. There is growing concern as the development of antibiotics is slower than the increase in the resistance of pathogenic bacteria. Antimicrobial peptides (AMPs) are promising alternatives to antibiotics. Despite t...

Full description

Saved in:
Bibliographic Details
Published in:The journal of microbiology 2021, 59(2), , pp.113-123
Main Authors: Ryu, Minkyung, Park, Jaeyeong, Yeom, Ji-Hyun, Joo, Minju, Lee, Kangseok
Format: Article
Language:English
Subjects:
Antibiotic resistance
Antibiotics
Anticancer properties
Antiinfectives and antibacterials
Antimicrobial activity
Antimicrobial agents
Antimicrobial peptides
Antioxidants
Antiviral agents
Barriers
Biomedical and Life Sciences
Chemical compounds
Clinical trials
Disease resistance
Fungicides
Insecticide resistance
Insecticides
Life Sciences
Microbiology
Microorganisms
Minireview
Pathogenic bacteria
Peptides
Pharmacology
Side effects
Specificity
생물학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In recent years, the occurrence of antibiotic-resistant pathogens is increasing rapidly. There is growing concern as the development of antibiotics is slower than the increase in the resistance of pathogenic bacteria. Antimicrobial peptides (AMPs) are promising alternatives to antibiotics. Despite their name, which implies their antimicrobial activity, AMPs have recently been rediscovered as compounds having antifungal, antiviral, anticancer, antioxidant, and insecticidal effects. Moreover, many AMPs are relatively safe from toxic side effects and the generation of resistant microorganisms due to their target specificity and complexity of the mechanisms underlying their action. In this review, we summarize the history, classification, and mechanisms of action of AMPs, and provide descriptions of AMPs undergoing clinical trials. We also discuss the obstacles associated with the development of AMPs as therapeutic agents and recent strategies formulated to circumvent these obstacles.
ISSN:1225-8873
1976-3794
DOI:10.1007/s12275-021-0649-z